Anti-a-enolase is a prognostic marker in postoperative lung cancer patients

Kuan Chung Hsiao, Neng Yao Shih, Pei Yi Chu, Yi Mei Hung, Jia Yi Liao, Shao Wen Chou, Yi Yuan Yang, Gee Chen Chang, Ko Jiunn Liu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Our previous studies suggest that antibodies against ENO1 (anti-ENO1 Ab) have a protective role in patients with non-small cell lung carcinoma. In this study, we evaluated the prognostic value of anti-ENO1 Ab levels in non-small cell lung carcinoma patients undergoing surgery. Circulating levels of anti-ENO1 Ab were assessed in 85 non-small cell lung carcinoma patients before and after surgery, and were correlated with clinical outcome. After surgery, patients with a higher increase of anti-ENO1 Ab had a lower hazard ratio and a better progression-free survival. Using animal models, we demonstrated that tumor cells reduce the circulating levels of anti-ENO1 Ab through physical absorption and neutralization of anti-ENO1 Ab with surface-expressed and secreted ENO1, respectively. Mice transplanted with ENO1-overexpressing tumors generated ENO1-specific regulatory T cells to suppress the production of anti-ENO1 Ab. Our results suggest that the increase of anti-ENO1 Ab may reflect anti-tumor immune responses and serve as a prognostic marker in postoperative lung cancer patients.

Original languageEnglish
Pages (from-to)35073-35086
Number of pages14
JournalOncotarget
Volume6
Issue number33
DOIs
Publication statusPublished - 2015

Keywords

  • ENO1
  • Lung cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Anti-a-enolase is a prognostic marker in postoperative lung cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Hsiao, K. C., Shih, N. Y., Chu, P. Y., Hung, Y. M., Liao, J. Y., Chou, S. W., Yang, Y. Y., Chang, G. C., & Liu, K. J. (2015). Anti-a-enolase is a prognostic marker in postoperative lung cancer patients. Oncotarget, 6(33), 35073-35086. https://doi.org/10.18632/oncotarget.5316